Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Biotechnology

Healthcare
$3.72 +1.71%

+$0.06 today

Market cap
$284.14M
Beta
2.92
P/E (TTM)
-3.6
EPS (TTM)
-$1.00
52W Low $2.83High $15.74

Volume 0.63M

Average 1.78M

FULC Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Fulcrum Therapeutics, Inc.NASDAQ: FULC

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $3.86M rose 21.9% year over year, ahead of the -4.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 25.9% from the prior quarter. Over 3 fiscal years it compounded at -2.3% a year.

Context

  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +21.9% holds above the trailing-twelve-month pace of -4.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.86M+25.9% QoQ
Last fiscal yearDec 2025
$12.47M-14.3% YoY
LTMMar 2026
$13.16M-4.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.9%——
1 year-14.3%——
3-year CAGR-2.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
12.47M USD
Year-over-year change
-14.3%
4-year CAGR
+3.0%

Stock-Based Compensation vs competitors

How FULC compares with its peers on the latest reported figures

  • FULC's LTM Mar 2026 stock-based compensation of $13.16M is the 2nd largest of the 10 companies compared; the peer median is $9.22M.
  • Its year-over-year change of -4.7% is the 6th highest of 10, against a peer median of +2.5%.
  • Over three fiscal years its annual growth of -2.3% compares with a peer median of +8.6%.
FULC Competitors Peer median
Stock-Based Compensation for FULC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$27.96M -33.3%+53.3%—
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$13.16M -4.7%-2.3%—
ADCTADC Therapeutics S.A.LTM Mar 2026$12.63M +26.4%-48.5%16.0%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$12.55M +2.5%+2.8%18.0%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$10.93M +20.5%+16.2%—
OCGNOcugen, Inc.LTM Mar 2026$9.22M +22.1%-9.9%206.5%
OMEROmeros CorporationLTM Mar 2026$5.74M +13.3%—58.0%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$4.71M -8.3%+3.5%31.8%
NGNENeurogene Inc.LTM Mar 2026$3.41M -69.9%+124.6%—
BCYCBicycle Therapeutics plcLTM Mar 2026$2.68M -107.0%+13.8%4.2%
Peer median (excluding FULC) $9.22M+2.5%+8.6%24.9%

Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(80.85M)(109.87M)(97.34M)(9.73M)(74.88M)
Depreciation & Amortization2.52M2.41M2.17M1.59M1.39M
Deferred Income Tax00000
Stock-Based Compensation11.07M13.35M14.8M14.55M12.47M
Change in Working Capital(11.89M)(3.09M)(4.61M)(4.25M)3.91M
Accounts Receivables(500K)2.5M(308K)(1.56M)2.1M
Inventory1.25M0000
Accounts Payables973K(1.18M)(853K)(1.59M)428K
Other Working Capital(13.61M)(4.42M)(3.45M)(1.1M)1.39M
Other Non-Cash Items673K152K(5.99M)(4.39M)(2.95M)
Operating Cash Flow(78.48M)(97.05M)(90.97M)(2.22M)(60.07M)
Capital Expenditures(1.71M)(1.96M)(508K)(278K)(314K)
Acquisitions (Net)127.96M(14.38M)000
Purchases of Investments(216.23M)(151.15M)(194.89M)(178.59M)(180.22M)
Sales of Investments88.28M165.53M158.71M211.1M211.25M
Other Investing Activities(127.96M)14.38M000
Investing Cash Flow(129.67M)12.41M(36.69M)32.23M30.72M
Debt Repayment(18K)0000
Common Stock Issued182.86M80.8M117.35M2.75M168.67M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.67M3.52M777K00
Financing Cash Flow186.51M84.32M118.12M2.75M168.67M
Effect of Forex Changes00000
Net Change in Cash(21.64M)(314K)(9.54M)32.76M139.32M
Free Cash Flow(80.19M)(99.01M)(91.47M)(2.5M)(60.38M)

Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Intrinsic Alpha fair value

Locked

Current Price

$3.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.